No 16 (2014)
News. Findings and events
Chronic obstructive pulmonary disease
6-11 1502
Abstract
Glycopyrronium is a new powerful quick-acting anticholinergic bronchodilator for the treatment of chronic obstructive pulmonary disease. Glycopyrronium is powder in Breezhaler® inhalation device. The review tells about phase III clinical trials demonstrating the positive effect of glycopyrronium on lung function, symptoms of the disease, exercise tolerance, frequency of severe and moderate COPD exacerbations and quality of life of patients. The drug showed good tolerability and high cardiac safety in a long-term period.
Bronchial asthma
12-17 517
Abstract
Sound approach to patient management is based on the evaluation of the overall clinical and functional pattern of the disease, including RF changes and other parameters. According to its concept, personalized treatment should be regarded as a specific creative process based on international guidelines and achievements of the modern healthcare.
18-23 575
Abstract
Sound approach to patient management is based on the evaluation of the overall clinical and functional pattern of the disease, including RF changes and other parameters. According to its concept, personalized treatment should be regarded as a specific creative process based on international guidelines and achievements of the modern healthcare.
28-31 455
Abstract
The purpose of the article is to define the place of the combination bronchodilator Berodual N in the treatment of bronchial asthma exacerbations and provide recommendations on different routes of administration depending on the severity of asthma exacerbations.
32-35 477
Abstract
The article presents data on the efficacy and safety of ciclesonide in the treatment of patients with bronchial asthma; the drug is compared with other inhaled corticosteroids
PNEUMONIA
36-43 412
Abstract
The article is devoted to the role of respiratory fluoroquinolones in the treatment of community-acquired pneumonia. Respiratory fluoroquinolones are key in the treatment of the disease as they affect virtually all pathogens of community-acquired pneumonia, and have attractive pharmacokinetic and pharmacodynamic profiles. The article tells about the results of several multicenter clinical trials of moxifloxacin and its use as a second-line therapy in tuberculosis of the respiratory tract.
44-47 627
Abstract
The article is an overview of studies on morbidity and mortality from community-acquired pneumonia worldwide. There is data on the Republic of Tatarstan over the last two decades
Rational pharmacotherapy
48-55 462
Abstract
ARVI is the most common group of mass diseases and number one among infectious diseases. Adequate protection against influenza and ARVI can be achieved with the help of modern drugs that create a barrier on the way of the virus and increase the body's defenses.
56-60 465
Abstract
The article describes the etiology and clinical picture of cough in children with respiratory tract infections. The principles of rational choice of antibacterial drugs based on the sensitivity of the main pathogens are considered. The feasibility of beta-lactam antibiotics for coughs in children is demonstrated, which clinical and microbiological efficacy and strong safety profile was confirmed by randomized clinical trials.
Practice
61-64 946
Abstract
One of the most common systemic defects in patients with chronic obstructive pulmonary disease is skeletal and respiratory muscle dysfunction. Physical exercise in the therapy of such patients therefore plays an important role. The Institute of Pulmonology of the Russian FMBA has developed a system of special physical exercises to decrease dysfunction of respiratory and skeletal muscles and affect the hyperinflation of the lungs. The physical program includes strength exercises for upper and lower skeletal muscles, breathing exercises, training of the respiratory muscles using simulators and high-frequency chest wall oscillation.
ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)
ISSN 2658-5790 (Online)